Walnut Venture Associates — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
AltrixBioaltrixbio.comApr 2025
AltrixBio develops AJN003, a non-systemic, once-daily oral therapy for type 2 diabetes and related metabolic conditions that transiently coats the stomach and upper intestine to shift nutrient sensing and trigger a metabolic reset similar to bariatric surgery.
BiotechDigital HealthWilmington, US
Jeffrey Karp(Director)Ali Tavakkoli(Co-founder)Nancy Briefs(Executive Chair of the Board & Founder)Jeff Karp(Co-founder)
BoardJohn Brooks(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.